Lilly's Retevmo Meets Primary Endpoint in Phase 3 LIBRETTO-432 RET+ NSCLC Trial (LLY)

Eli Lilly's (LLY) oncology drug Retevmo (selpercatinib) has met the primary endpoint of progression-free survival in the Phase 3 LIBRETTO-432 trial for RET fusion-positive non-small cell lung cancer (NSCLC) in the adjuvant setting. The randomized, placebo-controlled study evaluated Retevmo versus placebo in patients with early-stage RET+ NSCLC who had undergone complete resection. Topline results are expected in the first half of 2026, with potential to expand Retevmo's label and market reach in lung cancer treatment.